Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions

Purpose of investigation: To determine whether the addition of the Hybrid Capture II (HC II) test (Digene Corp., Gaithersburg, MD, USA) to cytological, colposcopical and histological results could reduce the number of surgical treatment procedures for precancerous cervical lesions.

Methods: Surgical treatment of precancerous cervical lesions was performed in 181 women. Priorly, the women were tested for high-risk human papillomavirus (HPV). Sensitivity, specificity, positive and negative predictive value were calculated to assess the performance characteristics of HC II in the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) and grade 3 or worse (CIN 3+).

Results: Eighty (44.2%) women had a histological result < CIN 2; 117 (64.6%) women had < CIN 3. Fifty-three (29.3%) women with < CIN 2 tested HPV negative; 69 (38.1%) women with < CIN 3 tested HPV negative (p < 0.05). The sensitivity of HC II for detecting CIN 2+ and CIN 3+ was 76.2% and 87.5%, respectively.

Conclusion: A high proportion of women were overtreated probably due to cytological and histological overestimations. HPV testing would reduce the number of unnecessary surgical treatments and should be used as an additional screening tool.

Human papillomavirus; Precancerous cervical lesion; Surgical treatment; HPV testrng

[1] Pohar-Marinsek Z., Pogacnik A.: "Cytopathology in Slovenia" Cytopathology , 2004, 15, 1, 53.

[2] Cancer incidence in Slovenia 2000. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Slovenia, 2003.

[3] Parkin D.M.: "Global cancer statistics in the year 2000". Lancet Oneal., 2001, 2, 9, 533.

[4] Parkin D.M., Bray Fl., Devesa S.S.: "Cancer burden in the year 2000. The global picture". Eur. J. Cancer, 2001, 37 (suppl. 8), S4.

[5] Lutz J.M., F rancisci S., Mugno E., Usel M., Pompc-Kirn V., Coebergh J.W . et al.: "Cancer prevalence in Central Europe: the EUROPREVAL Study". Ann. Oneal., 2003, 14, 2, 313.

[6] Wright T.C. Jr., Cox J.T., Massad L.S., Carlson J., Twiggs L.B., Wilkinson E.J.: "2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia". Am. J. Obstet. Gynecol., 2003, 189, 1, 295.

[7] Wright T.C. Jr., Cox J.T., Massad L.S., Twiggs L.B., Wilkmson E.J.: "2001 Consensus Guidelines for the management of women with cervical cytological abnormalities". JAMA, 2002, 287, 16, 2120.

[8] Syrjanen K.J.: "Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV)". Eur. J. Obstet. Gynecol. Reprod. Biol., 1996, 65, 1, 45.

[9] Iatrakis G., Kourounis G., Georgopoulos N., Karachotzitis J.: 'Treatment delay and pathology results in women with low-grade squamous intraepithelial lesions. A preliminary study". Eur. J Gynaecol. Oneal., 2004, 25, 3, 376.

[10] Walboomers J.M., Jacobs MV, Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al.: "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide". J. Pathol., 1999, 189, 1, 12.

[11] Bosch F.X., Munoz N.: "The viral etiology of cervical cancer" Virus. Res., 2002, 89, 2, 183.

[12] Poljak M., Brencic A., Seme K., Vince A., Marin I.J.: "Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer". J. Clin. Microbiol., 1999, 37, 3, 796.

[13] Manos M.M., Kinney WK., Hurley L.B., Sherman M.E., ShiehNgai J., Kurman R.J. et al.: "Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results". JAMA, 1999, 281, 17, 1605.

[14] Manos M.M.: "HPY testing for clarilying borderline cervical smear results". B1: Med. J., 2001, 322, 7291, 878.

[15] Lytwyn A., Sellors J.W., Mahony J.B., Daya D., Chapman W., Ellis N. et al.: "Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPY effectiveness in Lowgrade Paps (HELP) Study No. I Group". C.M.A.J., 2000, 163, 6, 701.

[16] Petry K.U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B. et al.: "Inclusion of HPY testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients". Br. J. Cancer, 2003, 88, 10, 1570.

[17] Wright T.C. Jr., Schiffman M.: "Adding a test for human papillomavirus DNA to cervical-cancer screening". N. Engl. J. Med., 2003, 348, 6, 489.

[18] Wright T.C. Jr., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S. ct al.: "Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening". Ohstet. Gynecol., 2004, 103, 2, 304.

[19] Agnantis N.J., Sotiriadis A., Paraskevaidis E.: "The current status of HPY DNA testing". Eur. J. Gynaecol. Oncol., 2003, 24, 5, 351.

[20] Kim J.J., Wright T.C., Goldie SJ.: "Cost-effectiveness of alternalive triage strategies for atypical squamous cells of undetermined significance". J.A.M.A., 2002, 287, 18, 2382.

[21] Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H.. Luesley D. et al.: "Management of women who test positive for high-risk types of human papillomavirus: the H ART study" Lancet, 2003, 362, 9399, 1871.

[22] Nieminen P.,V uorma S.. Viikki M.. Hakama M.,A nttila A.: "Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer". Bi: J. Obstet. Gynaecol., 2004, 111, 8, 842.

[23]Vrtacnik-Bokal E., Rakar S., Moiina A., Poljak M.: "Human papilloma virus infection in relation to mild dyskaryosis in conventional cervical cytology". Eur. J. Gynaecol. Oncol. (accepted for publication).